Oncternal Therapeutics, Inc. Quarterly Common Stock, Shares Authorized from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Oncternal Therapeutics, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2010 to Q3 2024.
  • Oncternal Therapeutics, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 120M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 120M 0 0% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 120M 0 0% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 120M 0 0% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 120M 0 0% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 120M 0 0% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 120M 0 0% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 120M 0 0% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 120M +60M +100% Dec 31, 2022 10-K 2024-03-07
Q3 2022 120M 0 0% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 120M 0 0% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 120M +60M +100% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 60M 0 0% Dec 31, 2021 10-K 2023-03-09
Q3 2021 120M +60M +100% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 120M +60M +100% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 60M 0 0% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 60M 0 0% Dec 31, 2020 10-K 2022-03-10
Q3 2020 60M 0 0% Sep 30, 2020 10-Q 2020-11-04
Q2 2020 60M 0 0% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 60M 0 0% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 60M -140M -70% Dec 31, 2019 10-K/A 2021-03-12
Q3 2019 60M 0 0% Sep 30, 2019 10-Q 2019-11-08
Q2 2019 60M 0 0% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 60M 0 0% Mar 31, 2019 10-Q 2019-05-10
Q4 2018 200M +140M +233% Dec 31, 2018 10-K 2020-03-16
Q3 2018 60M 0 0% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 60M 0 0% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 60M 0 0% Mar 31, 2018 10-Q 2018-05-15
Q4 2017 60M 0 0% Dec 31, 2017 10-K 2019-03-18
Q3 2017 60M -340M -85% Sep 30, 2017 10-Q 2017-11-14
Q2 2017 60M -340M -85% Jun 30, 2017 10-Q 2017-08-14
Q1 2017 60M -340M -85% Mar 31, 2017 10-Q 2017-05-15
Q4 2016 60M -340M -85% Dec 31, 2016 10-K 2018-03-13
Q3 2016 400M 0 0% Sep 30, 2016 10-Q 2016-11-07
Q2 2016 400M 0 0% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 400M +200M +100% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 400M +200M +100% Dec 31, 2015 10-K 2017-03-24
Q3 2015 400M +200M +100% Sep 30, 2015 10-Q 2015-11-09
Q2 2015 400M +200M +100% Jun 30, 2015 10-Q 2015-08-10
Q1 2015 200M +80M +66.7% Mar 31, 2015 10-Q 2015-05-11
Q4 2014 200M +80M +66.7% Dec 31, 2014 10-K 2016-03-15
Q3 2014 200M +80M +66.7% Sep 30, 2014 10-Q 2014-11-10
Q2 2014 200M +80M +66.7% Jun 30, 2014 10-Q 2014-08-05
Q1 2014 120M 0 0% Mar 31, 2014 10-Q 2014-05-12
Q4 2013 120M 0 0% Dec 31, 2013 10-K 2015-03-16
Q3 2013 120M 0 0% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 120M 0 0% Jun 30, 2013 10-Q 2013-07-22
Q1 2013 120M 0 0% Mar 31, 2013 10-Q 2013-05-06
Q4 2012 120M 0 0% Dec 31, 2012 10-K 2014-03-12
Q3 2012 120M 0 0% Sep 30, 2012 10-Q 2012-11-08
Q2 2012 120M 0 0% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 120M 0 0% Mar 31, 2012 10-Q 2012-05-10
Q4 2011 120M +60M +100% Dec 31, 2011 10-K 2013-03-05
Q3 2011 120M Sep 30, 2011 10-Q 2011-11-04
Q2 2011 120M Jun 30, 2011 10-Q 2011-08-09
Q1 2011 120M May 6, 2011 10-K 2014-03-12
Q4 2010 60M Dec 31, 2010 10-K 2012-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.